ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth

[cafead]

via

• Proceeds enable expansion and scale of ElevateBio’s cell and gene technology platforms, end-to-end capabilities, and therapeutic pipeline to serve an increasing number of biopharmaceutical partners and drive revenue growth
• ElevateBio has added more than 15 new biopharma partners across its ecosystem over the past year, including strategic gene editing collaborations with Moderna and Novo Nordisk

article source